An open-label, randomized, clinical study assessing the safety and immunogenicity of JVC-001 in Japanese healthy children

Phase 2, randomised, open-label trial of measles, mumps and rubella vaccine (live) in measles, rubella and mumps (2 arms), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoints: Seroconversion rate for measles virus antibodies at Day 42 and Seroconversion rate for rubella virus antibodies at Day 42. Started Oct 2015; status: completed.